Trending...
- Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
- François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
- Off The Hook YS (NY SE: OTH) Executes Transformational Apex Acquisition, Creating Vertically Integrated Marine Powerhouse with $60M Inventory Capacity
Proposed five-year agreement positions Covalent Medical to commercialize ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye portfolio across physician-dispensed and national retail channels, with launch targeted for Q1 2027
DALLAS - ncarol.com -- ClearSight Therapeutics Signs Letter of Intent with Covalent Medical to Expand OTC Eye Care Portfolio Through Multi-Channel Commercial Partnership
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on ncarol.com
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on ncarol.com
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on ncarol.com
- CCHR Says Psychiatry's Admission on Antidepressant Withdrawal Comes Far Too Late
- 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
- As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
- AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
- Average US gambler spends $210 per month in 2026
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on ncarol.com
- 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
- Integris Composites developing armor for military in Arctic Circle
- Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards
- Workplace safety ideas from the front lines to highlight Applied Ergonomics Conference in Arlington, Texas
- OpenSSL Corporation Advisory Committees' Elections 2026: Results Announcement
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
Source: ClearSight Therapeutics, Inc.
0 Comments
Latest on ncarol.com
- Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
- $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
- Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
- Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
- Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
- PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
- Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
- Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
- Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
- DASH Carolina RDU Sets the Pace in 2025 with Record-Breaking Sales and Team Excellence
- Wespor Business Launches AI Voice and Chat Agents to Help Triangle Small Businesses Capture Missed Leads
- America's Boating Club Ushers in New Board at Change of Watch
- FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
- $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
- CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
- PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
- Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
- From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
- Cold. Clean. Anywhere. Meet FrostSkin
- How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment